GlassScriptPhysician profile
James B Stewart
NPI 1194702639
$6,344.40
in general payments reported to CMS, 2019-2025
25 companies · $1,266 in 2025
The $1,266 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $197 · 2021: $851 · 2022: $517 · 2023: $1,332 · 2024: $1,710 · 2025: $1,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,952 · Entertainment: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,952.31 |
| Entertainment | $356.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $788.03 | 2019-2025 | Cequa |
| Glaukos Corporation | $765.32 | 2023-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Radius |
| Allergan, INC. | $585.84 | 2019-2022 | |
| Alcon Vision LLC | $568.31 | 2019-2025 | Rocklatan, Dailies Total1 Multifocal, Wavelight Refractive Suite |
| Abbvie INC. | $559.14 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb Americas INC. | $430.42 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $356.86 | 2022-2025 | Acthar |
| Optos, INC. | $356.23 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $262.16 | 2019-2025 | Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $233.04 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $195.88 | 2021 | |
| Biotissue Holdings INC. | $172.13 | 2021-2024 | |
| Dompe US, INC. | $167.08 | 2024-2025 | Oxervate |
| Lkc Technologies, INC. | $133.05 | 2024 | |
| Kala Pharmaceuticals, INC. | $124.93 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $115.65 | 2023 | Acuvue |
| Horizon Therapeutics Plc | $115.20 | 2023 | Tepezza |
| Rxsight INC | $103.05 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.52 | 2019-2021 | |
| Oyster Point Pharma, INC. | $95.10 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $52.77 | 2019-2020 | |
| New World Medical,INC. | $20.84 | 2021 | |
| Amgen INC. | $17.73 | 2025 | Tepezza |
| Sight Sciences, INC. | $13.12 | 2024 | Omni Surgical System |
| Lensar, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.